Search research articles
Contact Us
Filters
Showing results (201-210 of 224) with videos related to
Page
of 23
Sort By:
Ebiomedicine
|
January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancer
Manon Réda, Corentin Richard, Aurelie Bertaut, et al.
BMC Cancer
|
July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
BMC Cancer
|
April 27, 2020
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Stefano Kim, Bruno Buecher, Thierry André, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
The Lancet. Oncology
|
October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Cancer Immunology Research
|
October 20, 2025
Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy
Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies
Morgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
David Malka, Eric François, Frédérique Penault-Llorca, et al.
The Lancet. Oncology
|
January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
The Lancet. Oncology
|
July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
Stefano Kim, Eric François, Thierry André, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 224) with videos related to
Sort By:
Page
of 23
Ebiomedicine
|
January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancer
Manon Réda, Corentin Richard, Aurelie Bertaut, et al.
BMC Cancer
|
July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
BMC Cancer
|
April 27, 2020
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Stefano Kim, Bruno Buecher, Thierry André, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
The Lancet. Oncology
|
October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Cancer Immunology Research
|
October 20, 2025
Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy
Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies
Morgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
David Malka, Eric François, Frédérique Penault-Llorca, et al.
The Lancet. Oncology
|
January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
The Lancet. Oncology
|
July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
Stefano Kim, Eric François, Thierry André, et al.
Page
of 23